CEO

Dr Kathryn Antioch

Dr Kathryn Antioch

CEO, Guidelines and Economists Network International (GENI)

GAICD,   PhD  (Health Economics)   MSc,   BA (Hons),   AFCHSM CHM

Kathryn is CEO, Guidelines and Economists Network International (GENI), Principal Management Consultant, Health Economics and Funding Reforms, Adjunct Senior Lecturer, Department of Epidemiology and Preventive Medicine, Monash University.

She has over 25 years working in senior roles in Government, Private and NFP sectors including Federal and State Governments, Victorian hospitals, Canadian Royal Commission and GENI. Her leadership roles involve health policy and funding reforms, hospital and government administration and translational research in medicine and economics. She has worked on national pandemic planning.

Kathryn’s work concerned the COAG 2016 Heads of Agreements on Public Hospitals and stakeholder engagement in 2016 and 2017 involving five jurisdictions, Senate Inquiries, and Independent Hospital Pricing Authority (IHPA). She presented ‘Australian COAG national health reforms 2017-2020 Implications for the private sector’ as an invited speaker at the 2017 Annual Health Insurance Summit.

From 2010 to 2021, she participated in 18 Australian Senate inquiries on health policy and legislation, including COVID-19. This followed her three Council of Australian Governments (COAG) briefs on National Health Reform Agreements, which included recommendations from her stakeholder engagement across all Australian States and Territories and NZ. Stakeholder engagement was funded by consultancy contracts with Australian Health Care and Hospitals Association (AHHA) and Women’s and Children’s Health Care Australasia.

She was involved in national pandemic planning as a consultant working with the Australian National University and Royal Australian College of General Practitioners for the National Health and Medical Research Council (NHMRC).  Dr Antioch was contracted as an appointee to a 2018 Department of  Foreign Affairs and Trade (DFAT) Scientific Advisory Committee. During 2018, she undertook a  consultancy on Cost Benefit Analysis models to evaluate infrastructure impacting on environmental health.

As CEO GENI, she  forges links with national bodies that set standards, regulation and funding processes. This aims to achieve cost effectiveness in healthcare delivery, equity in related funding and Value Based Health Care.  She also leads translational research work in  medicine and economics concerning COVID-19, vaccinations, diabetes, cancer, cystic fibrosis, orphan drugs, Non-Communicable Diseases, and clinical guidelines. This contributes to  the international and Australian  health reform agenda.

She has held consultancy contracts with the World Health Organisation (WHO) on clinical guidelines;  Price Waterhouse Coopers (PWC) and the Independent Hospital Pricing Authority (IHPA) on reviewing  costs and  2015-16 hospital pricing reforms  for Activity Based Funding (ABF);  Federal and Victorian Governments, Local Hospital Networks, Centres of Excellence, NHMRC, Universities,  AHHA, private sector, Frontier Economics and World Bank.

She worked in senior roles in Federal and Victorian governments on  funding and health policy. Federally, it concerned Commonwealth-State health agreements, health insurance and ABF classification. In the  Victorian Department of Human Services (DHS) she worked on a state-wide Corporate Services Review, State-wide hospital budget negotiations with Treasury, hospital funding reforms, Ministerial Reviews and an evaluation of hospital networks for Cabinet Sub-Committee.

In three Victorian Local Hospital Networks (LHNs), including Alfred Health, Western Health and Inner and Eastern Health Care network, she led translational research in medicine and economics working with clinicians in  implementing such evidence into clinical protocols and guidelines. She negotiated $14m in hospital funding for Alfred Health in negotiations with the  Victorian Department of Human Services using new risk adjustment methods. She worked on performance review and service planning.  As Chair, Victorian Government’s Risk Adjustment Working Group she led  ABF reforms.

Her reforms are published in four editions of European Journal of Health Economics and Australian journals. Her recent contributions to the Australian reform agenda  are published in the 2017 edition of Cost Effectiveness and Resource Allocation (CERA) Journal and by the Australian Parliament.

She held Ministerial appointments to National Health and Medical Research Council (NHMRC) Health Advisory Committee, National Health Committee, Lead and Privacy Committees. She was a Board member of the Victorian Osteopaths Registration Board; Deputy Chair, GENI Board; Member, IHPA Deed of Standing Order Panel for ABF Advice: 2013 to 2018, and Australian Government Health Economics Expert Panel.  She worked on the British Columbia Royal Commission on Health Care and Costs, Canada

Dr Antioch was awarded Australian Institute of Company Directors 2019 Scholarship to undertake the International Company Directors Program and graduated in 2020. Monash University nominated her for the Victorian Premier’s Award for Health and Medical Research.  She received the Health Administrators’ Association of British Columbia Award for Scholarship and Leadership, University of British Columbia (UBC), Canada. Kathryn was awarded an Australian Public Service Post Graduate Award (Overseas) to undertake the  MSc graduate program at UBC.

She is Editorial board member, Cost Effectiveness and Resource Allocation (CERA) journal, prior Associate Editor, CERA. Kathryn authors 50 publications.

Contact: kathryn.antioch@monash.edu

  kantioch@yahoo.com.au

Click here for a list of publications

Click here for a list of National and International Presentations